Clinical management of inflammatory bowel disease in the organ recipient

doi:10.3748/wjg.v20.i13.3525

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 13

This Article

(288)

(346)

(0)

(7879)

(31)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Apr 7, 2014; 20(13): 3525-3533
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3525

Table 1 Interaction between inflammatory bowel disease therapy and anti-reject therapy in inflammatory bowel disease patients after liver transplantation

Drug	Efficacy		Ref.
Drug	IBD therapy	Anti-reject therapy
5-ASA	+		Ref.	[3]
	+		[12]
Prednisone	+	+	[12]
Prednisone	+	+	[21]
Azathioprine	+	+	[2]
Anti-TNFα	+		[15]
			[16]
			[13]
			[14]
			[18]
Tacrolimus	-	+	[2]
Tacrolimus	-	+	[3]
Cyclosporine	+	+	[3]
Mycophenolate	-	+	[22]
Mofetil	-	+	[23]

TNFα: Tumor necrosis factor alpha; IBD: Inflammatory bowel disease; 5-ASA: 5-aminosalicylates.

Full Size Table

Citation: Indriolo A, Ravelli P. Clinical management of inflammatory bowel disease in the organ recipient. World J Gastroenterol 2014; 20(13): 3525-3533
URL: https://www.wjgnet.com/1007-9327/full/v20/i13/3525.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i13.3525

Indriolo A, Ravelli P. Clinical management of inflammatory bowel disease in the organ recipient. World J Gastroenterol 2014; 20(13): 3525-3533 [PMID: 24707135 DOI: 10.3748/wjg.v20.i13.3525]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.